Analyzing Fluidigm Corporation (FLDM) and Simulations Plus (SLP)

Fluidigm Corporation (NASDAQ: FLDM) and Simulations Plus (NASDAQ:SLP) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their risk, institutional ownership, dividends, analyst recommendations, valuation, profitability and earnings.

Earnings & Valuation

This table compares Fluidigm Corporation and Simulations Plus’ revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio EBITDA Earnings Per Share Price/Earnings Ratio
Fluidigm Corporation $96.72 million 1.48 -$62.62 million ($2.46) -1.98
Simulations Plus $21.83 million 13.15 $9.15 million $0.32 52.03

Simulations Plus has higher revenue, but lower earnings than Fluidigm Corporation. Fluidigm Corporation is trading at a lower price-to-earnings ratio than Simulations Plus, indicating that it is currently the more affordable of the two stocks.

Dividends

Simulations Plus pays an annual dividend of $0.20 per share and has a dividend yield of 1.2%. Fluidigm Corporation does not pay a dividend. Simulations Plus pays out 62.5% of its earnings in the form of a dividend.

Volatility & Risk

Fluidigm Corporation has a beta of 3.37, indicating that its stock price is 237% more volatile than the S&P 500. Comparatively, Simulations Plus has a beta of -0.7, indicating that its stock price is 170% less volatile than the S&P 500.

Profitability

This table compares Fluidigm Corporation and Simulations Plus’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Fluidigm Corporation -74.05% -121.04% -18.55%
Simulations Plus 24.86% 23.21% 19.23%

Institutional & Insider Ownership

88.9% of Fluidigm Corporation shares are owned by institutional investors. Comparatively, 32.0% of Simulations Plus shares are owned by institutional investors. 4.7% of Fluidigm Corporation shares are owned by insiders. Comparatively, 36.9% of Simulations Plus shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Analyst Ratings

This is a breakdown of recent ratings and target prices for Fluidigm Corporation and Simulations Plus, as reported by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Fluidigm Corporation 0 0 1 0 3.00
Simulations Plus 0 0 0 0 N/A

Fluidigm Corporation currently has a consensus price target of $9.00, indicating a potential upside of 85.19%. Given Fluidigm Corporation’s higher probable upside, analysts clearly believe Fluidigm Corporation is more favorable than Simulations Plus.

Summary

Simulations Plus beats Fluidigm Corporation on 8 of the 14 factors compared between the two stocks.

About Fluidigm Corporation

Fluidigm Corporation creates, manufactures and markets technologies and life science tools focused on the exploration and analysis of single cells, as well as the industrial application of genomics, based upon the Company’s core microfluidics and mass cytometry technologies. The Company operates in the development, manufacturing and commercialization of life science tools for the life science and Ag-Bio industries segment. Its products include preparatory instruments, preparatory analytical instruments, analytical instruments, integrated fluidic circuits (IFCs), and assays and reagents. Its preparatory instruments include C1 Single-Cell Auto Prep System, Access Array System, Juno System and IFCs, and Callisto System and IFC. Its analytical instruments include Biomark HD System, EP1 System and Helios/CyTOF 2 System. Its assays and reagents include Delta Gene and SNP Type Assays, and Access Array Target-Specific Primers and Targeted Sequencing Prep Primers.

About Simulations Plus

Simulations Plus, Inc. (Simulations Plus) develops and produces software for use in pharmaceutical research and for education, and provides consulting and contract research services to the pharmaceutical industry. The Company offers five software products for pharmaceutical research. ADMET (Absorption, Distribution, Metabolism, Excretion and Toxicity) Predictor is a computer program that takes molecular structures as inputs and predicts over 140 different properties for them at the rate of about 200,000 compounds per hour. MedChem Designer includes a small set of ADMET Predictor property predictions, allowing the chemist to modify molecular structures. MedChem Studio is a tool for medicinal and computational chemists for both data mining and for designing new drug-like molecules. DDDPlus simulates in-vitro laboratory experiments used to measure the rate of dissolution of the drug. GastroPlus simulates the absorption, pharmacokinetics, and pharmacodynamics of drugs.

Receive News & Ratings for Fluidigm Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fluidigm Corporation and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply